Skip to main content

16 Result(s)

within Article Remove this filter H K Al-Ali Remove this filter Medicine/Public Health, general Remove this filter

and

  1. Article

    Erratum: A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

    Correction to: Leukemia advance online publication 18 November 2016; doi:10.1038/leu.2016.300 Following the online publication of this article, the authors noted that Dr McMullin was incorrectly excluded from ...

    A Tefferi, H K Al-Ali, G Barosi, T Devos, H Gisslinger, Q Jiang, J-J Kiladjian… in Leukemia (2017)

    Download PDF (34 KB) View Article

  2. Article

    Open Access

    A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

    RBC-transfusion dependence is common in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis. The objective of this study was to determine the rates of RBC-transfusion independence after the...

    A Tefferi, H K Al-Ali, G Barosi, T Devos, H Gisslinger, Q Jiang, J-J Kiladjian… in Leukemia (2017)

    Download PDF (246 KB) View Article

  3. Article

    Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

    Correction to: Leukemia (2016) 30, 1701–1707; doi:10.1038/leu.2016.148 Following the publication of this article the authors noted that the IPSS risk assignment was incorrectly listed in the second paragraph o...

    C N Harrison, A M Vannucchi, J-J Kiladjian, H K Al-Ali, H Gisslinger, L Knoops… in Leukemia (2017)

    Download PDF (82 KB) View Article

  4. Article

    Open Access

    Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

    Ruxolitinib is a Janus kinase (JAK) (JAK1/JAK2) inhibitor that has demonstrated superiority over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment...

    C N Harrison, A M Vannucchi, J-J Kiladjian, H K Al-Ali, H Gisslinger, L Knoops… in Leukemia (2016)

    Download PDF (461 KB) View Article

  5. No Access

    Article

    Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation

    Elevated serum ferritin contributes to treatment-related morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). The multicenter DE02 trial assessed the safety, efficacy and im...

    N Jaekel, K Lieder, S Albrecht, O Leismann, K Hubert, G Bug… in Bone Marrow Transplantation (2016)

  6. No Access

    Article

    Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients

    U Platzbecker, H K Al-Ali, N Gattermann, D Haase, V Janzen, J Krauter, K Götze… in Leukemia (2014)

  7. No Access

    Article

    Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib

    The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing symptomatic splenomegaly and myelofibrosis (MF)-related symptoms. However, allogeneic hematopoietic cell transplant...

    N Jaekel, G Behre, A Behning, C Wickenhauser, T Lange… in Bone Marrow Transplantation (2014)

  8. No Access

    Article

    The impact of the age of HLA-identical siblings on mobilization and collection of PBSCs for allogeneic hematopoietic cell transplantation

    With the increasing age of patients undergoing allogeneic hematopoietic cell transplantation (HCT), the age of matched related sibling donors (MRDs) is expected to increase. Donor safety and the impact of dono...

    H K Al-Ali, M Bourgeois, R Krahl, E Edel, S Leiblein… in Bone Marrow Transplantation (2011)

  9. No Access

    Article

    Monitoring of WT1 expression in PB and CD34+ donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning

    Relapse of malignant disease remains the major complication in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after hematopoietic cell transplantation (HCT) with reduced-intensity...

    T Lange, M Hubmann, R Burkhardt, G-N Franke, M Cross, M Scholz, S Leiblein… in Leukemia (2011)

  10. No Access

    Article

    UVA (UVA-1) therapy for the treatment of acute GVHD of the skin

    Long-wavelength UVA (340–400 nm UVA-1) phototherapy has been reported to be effective in atopic dermatitis, localized scleroderma and T-cell-derived skin diseases. We retrospectively investigated 70 patients w...

    M Schlaak, S Schwind, T Wetzig, J Maschke, R Treudler… in Bone Marrow Transplantation (2010)

  11. No Access

    Article

    Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR

    O Pelz-Ackermann, M Cross, H Pfeifer, M Deininger, S-Y Wang, H K Al-Ali… in Leukemia (2008)

  12. No Access

    Article

    A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

    Hematopoietic cell transplantation (HCT) is an effective treatment for myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML). In this study, outcome of 593 patients with MDS/sAML after autologous an...

    H K Al-Ali, R Brand, A van Biezen, J Finke, M Boogaerts, A A Fauser, M Egeler… in Leukemia (2007)

  13. No Access

    Article

    Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation

    T Lange, T Bumm, M Mueller, S Otto, H-K Al-Ali, L Grommisch, S Musiol, C Franke… in Leukemia (2005)

  14. No Access

    Article

    Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML

    A total of 24 patients (median age 58; range, 27–71 years) with chronic myeloid leukemia (CML) in first chronic (CP1) (n=14), second chronic (n=4), or accelerated phase (n=6) who were not candidates for conventio...

    F R Kerbauy, R Storb, U Hegenbart, T Gooley, J Shizuru, H K Al-Ali, J P Radich… in Leukemia (2005)

  15. No Access

    Article

    Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin

    Long-wavelength ultraviolet A (340–400 nm UVA1) phototherapy has been reported to be effective in atopic dermatitis, localized scleroderma and other T-cell-derived skin diseases. UVA1 as an adjunct to systemic...

    T Wetzig, M Sticherling, J-C Simon, U Hegenbart… in Bone Marrow Transplantation (2005)

  16. No Access

    Article

    Late-onset Epstein–Barr virus (EBV)-negative extranodal B-precursor lymphoblastic lymphoma of donor origin after hematopoietic stem cell transplantation (HSCT)

    M Bredt, G Schönfeld, W Kleeberger, E König, H Kröning… in Bone Marrow Transplantation (2003)